CY1124162T1 - Ενας συνδυασμος κυνουρενινης και αντιγονοπαρουσιαστικων κυτταρων (απκ) ως θεραπευτικες ουσιες και μεθοδοι για τη χρηση τους στην ανοσορυθμιση - Google Patents

Ενας συνδυασμος κυνουρενινης και αντιγονοπαρουσιαστικων κυτταρων (απκ) ως θεραπευτικες ουσιες και μεθοδοι για τη χρηση τους στην ανοσορυθμιση

Info

Publication number
CY1124162T1
CY1124162T1 CY20211100396T CY211100396T CY1124162T1 CY 1124162 T1 CY1124162 T1 CY 1124162T1 CY 20211100396 T CY20211100396 T CY 20211100396T CY 211100396 T CY211100396 T CY 211100396T CY 1124162 T1 CY1124162 T1 CY 1124162T1
Authority
CY
Cyprus
Prior art keywords
kynurenine
presenting cells
antigen presenting
immunoregulation
apc
Prior art date
Application number
CY20211100396T
Other languages
English (en)
Inventor
Aziz Ghahary
Reza B. JALILI
Ruhangiz T. Kilani
Yunyuan LI
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of CY1124162T1 publication Critical patent/CY1124162T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)

Abstract

Αυτή η εφεύρεση παρέχει συνδυασμούς κυνουρενίνης και αντιγονοπαρουσιαστικών κυττάρων (ΑΠΚ) για τη ρύθμιση της ανοσολογικής ανοχής, όπου οι συνδυασμοί μπορούν να χρησιμοποιηθούν για τη ρύθμιση μιας ανοσοαπόκρισης, η οποία μπορεί να είναι χρήσιμη στην αντιμετώπιση του σακχαρώδους διαβήτη τύπου 1 (ΣΔΤ1) ή της γυροειδούς αλωπεκίας (ΓΑ). Παρέχονται επίσης χρήσεις της κυνουρενίνης και των αντιγονοπαρουσιαστικών κυττάρων (ΑΠΚ) ως ανοσορυθμιστές για την αντιμετώπιση του ΣΔΤ1 ή της ΓΑ.
CY20211100396T 2014-09-26 2021-05-07 Ενας συνδυασμος κυνουρενινης και αντιγονοπαρουσιαστικων κυτταρων (απκ) ως θεραπευτικες ουσιες και μεθοδοι για τη χρηση τους στην ανοσορυθμιση CY1124162T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055823P 2014-09-26 2014-09-26
US201462087156P 2014-12-03 2014-12-03
PCT/CA2015/000506 WO2016044922A1 (en) 2014-09-26 2015-09-25 A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

Publications (1)

Publication Number Publication Date
CY1124162T1 true CY1124162T1 (el) 2022-05-27

Family

ID=55579987

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100396T CY1124162T1 (el) 2014-09-26 2021-05-07 Ενας συνδυασμος κυνουρενινης και αντιγονοπαρουσιαστικων κυτταρων (απκ) ως θεραπευτικες ουσιες και μεθοδοι για τη χρηση τους στην ανοσορυθμιση

Country Status (14)

Country Link
US (2) US20170209401A1 (el)
EP (1) EP3197466B1 (el)
JP (1) JP6898228B2 (el)
AU (1) AU2015321365B2 (el)
CA (1) CA2962655C (el)
CY (1) CY1124162T1 (el)
DK (1) DK3197466T3 (el)
ES (1) ES2867301T3 (el)
HU (1) HUE054020T2 (el)
MX (1) MX2017003808A (el)
PL (1) PL3197466T3 (el)
PT (1) PT3197466T (el)
RU (1) RU2727573C2 (el)
WO (1) WO2016044922A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190201360A1 (en) 2016-08-31 2019-07-04 Ampio Pharmaceuticals, Inc. Treatment of disease with n-acetyl kynurenine
US11712425B2 (en) 2018-03-14 2023-08-01 Albert Einstein College Of Medicine Immunoregulatory role of 3-OH-kynurenamine and uses thereof
CA3118682A1 (en) * 2018-11-04 2020-05-07 Figene, Llc Methods and compositions for treatment of type 1 diabetes using fibroblasts as facilitators of islet engraftment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US8313894B2 (en) * 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
AU2009279787B2 (en) * 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ITRM20080529A1 (it) * 2008-10-07 2010-04-08 Uni Degli Studi Perugia Uso della l-chinurenina e suoi derivati per la prevenzione ed il trattamento del diabete mellito di tipo 1.
EP2593480A2 (en) * 2010-07-15 2013-05-22 Technion Research & Development Foundation Ltd. Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012136815A1 (en) * 2011-04-08 2012-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Culture medium and method for obtaining a population of tolerogenic dendritic cells
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
JP2014111631A (ja) * 2014-01-31 2014-06-19 Tella Inc 樹状細胞の培養方法

Also Published As

Publication number Publication date
CA2962655C (en) 2022-08-09
JP6898228B2 (ja) 2021-07-07
AU2015321365A1 (en) 2017-04-20
RU2017114206A3 (el) 2019-04-30
EP3197466A4 (en) 2018-05-30
WO2016044922A1 (en) 2016-03-31
EP3197466B1 (en) 2021-02-17
PL3197466T3 (pl) 2021-09-13
US20230414550A1 (en) 2023-12-28
RU2727573C2 (ru) 2020-07-22
US20170209401A1 (en) 2017-07-27
ES2867301T3 (es) 2021-10-20
DK3197466T3 (da) 2021-05-10
CA2962655A1 (en) 2016-03-31
RU2017114206A (ru) 2018-10-26
PT3197466T (pt) 2021-05-14
JP2017528508A (ja) 2017-09-28
HUE054020T2 (hu) 2021-08-30
MX2017003808A (es) 2017-12-15
AU2015321365B2 (en) 2021-05-20
EP3197466A1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
CY1124162T1 (el) Ενας συνδυασμος κυνουρενινης και αντιγονοπαρουσιαστικων κυτταρων (απκ) ως θεραπευτικες ουσιες και μεθοδοι για τη χρηση τους στην ανοσορυθμιση
CY1124918T1 (el) Ρυθμιστες ccr2
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CY1123853T1 (el) Ρυθμιστες nrf2
CY1123459T1 (el) Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης
CY1123361T1 (el) Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου
CY1123917T1 (el) Ομοιοπολικα συνδεδεμενα δισωματα που εχουν ανοσοδραστικοτητα me pd-1 και lag-3, και μεθοδοι χρησης αυτων
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
BR112018072663A2 (pt) moduladores da via integrada ao estresse
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
CY1122012T1 (el) Ενωσεις ως ρυθμιστες του ror γαμμα
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
BR112019012343A2 (pt) anticorpos il-11ra
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CR20180518A (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
BR112019012342A2 (pt) anticorpos il-11
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
SV2017005373A (es) Inhibidores de la proteína quinasa c y métodos de su uso
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CY1120095T1 (el) Αναστολεις της erk και μεθοδοι χρησης